A novel recombinant pseudorabies virus expressing parvovirus VP2 gene: Immunogenicity and protective efficacy in swine

Virology Journal

Xiaoyu Wang³  Ling Zhu³  Dishi Chen³  Qian Shi¹  Yan Luo²  Qigui Yan³  Zhiwen Xu³  Wanzhu Guo³  Yang Chen³ 

[1] Center of Epizootic Prevention & Supervision of Sichuan, Chengdu, Sichuan, 610041, PR China;Sichuan Agricultural University Dujiangyan Campus, Dujiangyan, Sichuan, 611830, PR China;Animal Biotechnology Center of Sichuan Agricultural University, Ya'an, Sichuan, 625014, PR China

关键词: Protective Efficacy;    Immunogenicity;    VP2 gene;    Porcine parvovirus;    Recombinant pseudorabies virus;   

Others  :  1156535
DOI  :  10.1186/1743-422X-8-307

 received in 2011-03-08, accepted in 2011-06-16,  发布年份 2011

【 摘 要 】

Background

Porcine parvovirus (PPV) VP2 gene has been successfully expressed in many expression systems resulting in self-assembly of virus-like particles (VLPs) with similar morphology to the native capsid. Here, a pseudorabies virus (PRV) system was adopted to express the PPV VP2 gene.

Methods

A recombinant PRV SA215/VP2 was obtained by homologous recombination between the vector PRV viral DNA and a transfer plasmid. Then recombinant virus was purified with plaque purification, and its identity confirmed by PCR amplification, Western blot and indirect immunofluorescence (IFA) analyses. Electronic microscopy of PRV SA215/VP2 confirmed self-assembly of both pseudorabies virus and VLPs from VP2 protein.

Results

Immunization of piglets with recombinant virus elicited PRV-specific and PPV-specific humoral immune responses and provided complete protection against a lethal dose of PRV challenges. Gilts immunized with recombinant viruses induced PPV-specific antibodies, and significantly reduced the mortality rate of (1 of 28) following virulent PPV challenge compared with the control (7 of 31). Furthermore, PPV virus DNA was not detected in the fetuses of recombinant virus immunized gilts.

Conclusions

In this study, a recombinant PRV SA215/VP2 virus expressing PPV VP2 protein was constructed using PRV SA215 vector. The safety, immunogenicity, and protective efficacy of the recombinant virus were demonstrated in piglets and primiparous gilts. This recombinant PRV SA215/VP2 represents a suitable candidate for the development of a bivalent vaccine against both PRV and PPV infection.

【 授权许可】

   
2011 Chen et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Krakowka S, Ellis JA, Meehan B, Kennedy S, McNeilly F, Allan G: Viral wasting syndrome of swine: experimental reproduction of postweaning multisystemic wasting syndrome in gnotobiotic swine by co infection with porcine circovirus 2 and porcine parvovirus. Vet Pathol 2000, 37(3):254-63.
• [2]Kresse JI, Taylor WD, Stewart WW, Eernisse KA: Parvovirus infection in pigs with necrotic and vesicle-like lesions. Veterinary Microbiology 1985, 10(6):525-531.
• [3]Allan GM, Kennedy S, McNeilly F, Foster JC, Ellis JA, Krakowka SJ, Meehan BM, Adair BM: Experimental Reproduction of Severe Wasting Disease by Co-infection of Pigs with Porcine Circovirus and Porcine Parvovirus. Journal of Comparative Pathology 1999, 121(1):1-11.
• [4]Paul PS, Mengeling WL, Brown TT: Effect of vaccinal and passive immunity on experimental infection of pigs with porcine parvovirus. Am J Vet Res 1980, 41(9):1368-71.
• [5]Mengeling WL, Lager KM, Vorwald AC: The effect of porcine parvovirus and porcine reproductive and respiratory syndrome virus on porcine reproductive performance. Anim Reprod Sci 2000, 60-61:199-210.
• [6]Mengeling WL, Brown TT, Paul PS, Gutekunst DE: Efficacy of an inactivated virus vaccine for prevention of porcine parvovirus-induced reproductive failure. Am J Vet Res 1979, 40(2):204-7.
• [7]Martinez C, Dalsgaard K, Lopez de Turiso JA, Cortes E, Vela C, Casal JI: Production of porcine parvovirus empty capsids with high immunogenic activity. Vaccine 1992, 10(10):684-90.
• [8]Yuan Z, Zhang S, Liu Y, Zhang F, Fooks AR, Li Q, Hu R: A recombinant pseudorabies virus expressing rabies virus glycoprotein: safety and immunogenicity in dogs. Vaccine 2008, 26(10):1314-21.
• [9]Li X, Liu R, Tang H, Jin M, Chen H, Qian P: Induction of protective immunity in swine by immunization with live attenuated recombinant pseudorabies virus expressing the capsid precursor encoding regions of foot-and-mouth disease virus. Vaccine 2008, 26(22):2714-22.
• [10]Jiang Y, Fang L, Xiao S, Zhang H, Pan Y, Luo R, Li B, Chen H: Immunogenicity and protective efficacy of recombinant pseudorabies virus expressing the two major membrane-associated proteins of porcine reproductive and respiratory syndrome virus. Vaccine 2007, 25(3):547-60.
• [11]Lin Y, Qigai H, Xiaolan Y, Weicheng B, Huanchun C: The co-administrating of recombinant porcine IL-2 could enhance protective immune responses to PRV inactivated vaccine in pigs. Vaccine 2005, 23(35):4436-41.
• [12]Xu G, Xu X, Li Z, He Q, Wu B, Sun S, Chen H: Construction of recombinant pseudorabies virus expressing NS1 protein of Japanese encephalitis (SA14-14-2) virus and its safety and immunogenicity. Vaccine 2004, 22(15-16):1846-53.
• [13]Song Y, Jin M, Zhang S, Xu X, Xiao S, Cao S, Chen H: Generation and immunogenicity of a recombinant pseudorabies virus expressing cap protein of porcine circovirus type 2. Vet Microbiol 2007, 119(2-4):97-104.
• [14]Yin J, Ren X, Tian Z, Li Y: Assembly of pseudorabies virus genome-based transfer vehicle carrying major antigen sites of S gene of transmissible gastroenteritis virus: potential perspective for developing live vector vaccines. Biologicals 2007, 35(1):55-61.
• [15]van Zijl M, Wensvoort G, de Kluyver E, Hulst M, van der Gulden H, Gielkens A, Berns A, Moormann R: Live attenuated pseudorabies virus expressing envelope glycoprotein E1 of hog cholera virus protects swine against both pseudorabies and hog cholera. J Virol 1991, 65(5):2761-5.
• [16]Klupp BG, Hengartner CJ, Mettenleiter TC, Enquist LW: Complete, annotated sequence of the pseudorabies virus genome. J Virol 2004, 78(1):424-40.
• [17]Olsen LM, Ch'ng TH, Card JP, Enquist LW: Role of pseudorabies virus Us3 protein kinase during neuronal infection. J Virol 2006, 80(13):6387-98.
• [18]Kimman TG, de Wind N, Oei-Lie N, Pol JM, Berns AJ, Gielkens AL: Contribution of single genes within the unique short region of Aujeszky's disease virus (suid herpesvirus type 1) to virulence, pathogenesis and immunogenicity. J Gen Virol 1992, 73(Pt 2):243-51.
• [19]Chen L, Guo W, Xu Z, Wang X, Wang Y: The Biological Characteristics of a Gene-deleted Pseudorabies Virus Vaccine Strain (SA215). Chinese Journal of Animal and Veterinary Sciences 2005, 36(3):278-282.
• [20]Guo W, Xu Z, Wang X, Chen L, Wang Y, Wang M: Construction of new generation Pseudorabies virus gene deleted vaccine and the study of biologic characteristics. Journal of Sichuan Agricultural University 2000, 18(1):1-10.
• [21]Casal JI, Rueda P, Hurtado A: Use of parvovirus-like particles for vaccination and induction of multiple immune responses. Biotechnol Appl Biochem 1999, 29(Pt 2):141-50.
• [22]Zhou H, Yao G, Cui S: Production and purification of VP2 protein of porcine parvovirus expressed in an insect-baculovirus cell system. Virol J 2010, 7:366. BioMed Central Full Text
• [23]Casal JI: Parvovirus diagnostics and vaccine production in insect cells. Cytotechnology 1996, 20(1):261-270.
• [24]Antonis AFG, Bruschke CJM, Rueda P, Maranga L, Casal JI, Vela C, Hilgers Luuk AT, Belt Peter BGM, Weerdmeester K, Carrondo Manuel JT, Langeveld Jan PM: A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure. Vaccine 2006, 24(26):5481-5490.
• [25]Maranga L, Cunha A, Clemente J, Cruz P, Carrondo MJ: Scale-up of virus-like particles production: effects of sparging, agitation and bioreactor scale on cell growth, infection kinetics and productivity. J Biotechnol 2004, 107(1):55-64.
• [26]Casal JI, Rueda P, Hurtado A: Parvovirus-Like Particles as Vaccine Vectors. Methods 1999, 19(1):174-186.
• [27]Sedlik C, Saron M, Sarraseca J, Casal JI, Leclerc C: Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc Natl Acad Sci USA 1997, 94(14):7503-8.
• [28]Pan Q, He K, Huang K: Development of recombinant porcine parvovirus-like particles as an antigen carrier formed by the hybrid VP2 protein carrying immunoreactive epitope of porcine circovirus type 2. Vaccine 2008, 26(17):2119-2126.
• [29]Zuckermann FA: Aujeszky's disease virus: opportunities and challenges. Vet Res 2000, 31(1):121-31.